Person: ŞİMŞEK, MELİH
Pituitary Gland Metastasis of Breast Cancer: A Rare Case Report and Review of the Literature
2020-07-01T00:00:00Z, Şimşek, Melih, ŞİMŞEK, MELİH
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
2022-01-01T00:00:00Z, YASİN, Ayşe İrem, Aydin, Sabin Goktas, SÜMBÜL, BİLGE, KORAL, LOKMAN, ŞİMŞEK, MELİH, Geredeli, Caglayan, Ozturk, Akin, Perkin, Perihan, Demirtas, Derya, Erdemoglu, Engin, HACIBEKİROĞLU, İLHAN, Cakir, Emre, Tanrikulu, Eda, Coban, Ezgi, Ozcelik, Melike, Celik, Sinemis, Teker, Fatih, AKSOY, ASUDE, Firat, Sedat T., Tekin, Omer, Kalkan, Ziya, Turken, Orhan, Oven, Bala B., Dane, Faysal, Bilici, Ahmet, Isikdogan, Abdurrahman, ŞEKER, Mesut, TÜRK, HACI MEHMET, Gumus, Mahmut, YASİN, AYŞE İREM, SÜMBÜL, BİLGE, ŞİMŞEK, MELİH, ŞEKER, MESUT, TÜRK, HACI MEHMET
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov)
Diagnostic performance of apparent diffusion coefficient values for the differentiation of intrahepatic cholangiocarcinoma from gastrointestinal adenocarcinoma liver metastases
2021-12-22T00:00:00Z, Yilmaz, TEMEL FATİH, Gultekin, Mehmet Ali, Turk, Hacı Mehmet, Cesme, Dilek Hacer, Besiroglu, Mehmet, Simsek, Melih, Toprak, Huseyin, Alkan, ALPAY, YILMAZ, TEMEL FATİH, TÜRK, HACI MEHMET, ÇEŞME, DİLEK HACER, ŞİMŞEK, MELİH, ALKAN, ALPAY, TOPRAK, HÜSEYİN
Background: We aimed to investigate whether there is a difference between intrahepatic cholangiocarcinoma (IHCC) and liver metastases of gastrointestinal system (GIS) adenocarcinoma in terms of apparent diffusion coefficient (ADC) values. Patients and methods: From January 2018 to January 2020, we retrospectively examined 64 consecutive patients with liver metastases due to gastrointestinal system adenocarcinomas and 13 consecutive IHCC in our hospital's medical records. After exclusions, fifty-three patients with 53 liver metastases and 10 IHCC were included in our study. We divided the patients into two groups as IHCC and liver metastases of GIS adenocarcinoma. For mean apparent diffusion coefficient (ADCmean) values, the region of interests (ROI) was placed in solid portions of the lesions. ADCmean values of groups were compared. Results: The mean age of IHCC group was 62.50 ± 13.49 and mean age of metastases group was 61.15 ± 9.18. ADCmean values were significantly higher in the IHCC group compared to the metastatic group (p < 0.001). ROC curves method showed high diagnostic accuracy (AUC = 0.879) with cut-off value of < 1178 x 10-6 mm2/s for ADCmean (Sensitivity = 90.57, Specificity = 70.0, positive predictive value [PPV] = 94.1, negative predictive value [NPV] = 58.3) in differentiating adenocarcinoma metastases from IHCC. Conclusions: The present study results suggest that ADC values have a potential role for differentiation between IHCC and GIS adenocarcinoma liver metastases which may be valuable for patient management.
The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer
2022-05-01T00:00:00Z, ŞİMŞEK, MELİH, Yasin, Ayse, BEŞİROĞLU, MEHMET, TOPÇU, Atakan, SUCUOĞLU İŞLEYEN, ZEHRA, ŞEKER, Mesut, TÜRK, HACI MEHMET, ŞİMŞEK, MELİH, BEŞİROĞLU, MEHMET, TOPÇU, ATAKAN, SUCUOĞLU İŞLEYEN, ZEHRA, ŞEKER, MESUT, TÜRK, HACI MEHMET
Although vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease-19 (Covid-19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines against Covid-19 in patients with cancer. In this single-center, retrospective, cross-sectional, and descriptive study, the data of cancer patients referred to the medical oncology clinic of a university hospital were analyzed. The sample of the study consisted of cancer patients who had Covid-19 or were vaccinated against Covid-19. A total number of 2578 patients were included in the study. Of the patients, 2000 have never been infected with severe acute respiratory syndrome coronavirus and 578 patients have had a positive reverse-transcription polymerase chain reaction (RT-PCR) for Covid-19. It was found that 2094 patients (81.2%) were fully vaccinated, and 484 patients (18.8%) did not receive full-dose vaccination. A statistically significant difference in Covid-19 occurrence was found between the patients who had full-dose vaccination or not (p = 0.000). In in-group comparisons of full-dose vaccinated patients, while no difference was observed between two doses of BNT162b2 (Pfizer-BioNTech) and three doses of CoronaVac (p = 0.432), a statistically significant difference was observed between all other groups (p < 0.005). When the data of 578 patients who experienced Covid-19 was analyzed, a statistically significant difference was observed between the groups who were full-dose vaccinated and those who were not (p = 0.000). It is recommended that this vulnerable patient group should be prioritized in vaccination programs, and full-dose vaccination (at least two doses of vaccines) should be completed as soon as possible.
Mide kanserli hastaların demografik özelliklerinin sağ kalıma etkisi
2022-05-01T00:00:00Z, Karadeniz, Andaç, Bilici, Mehmet, Şimşek, Melih, ŞİMŞEK, MELİH
Efficacy and safety of trastuzumab emtansine in Her2 positive metastatic breast cancer: real world experience.
2021-05-20T00:00:00Z, Bahçeci, Aykut, Paydaş, Semra, Ak, Naziye, Ferhatoğlu, Ferhat, Saip, Pınar Mualla, Seydaoğlu, Gülşah, Bilici, Mehmet, Şimşek, MELİH, Tekin, Salim Başol, Çalikuşu, Züleyha, Yavuz, Sinan, Şahin, Ahmet Bilgehan, Çubukçu, Erdem, Evrensel, Türkkan, Değirmencioğlu, Serkan, Demiray, Atike Gökçen, Yumuk, Perran Fulden, Alan, Özkan, Çikman, Duygu İlke, Demirelli, Fuat Hulusi, Köstek, Osman, Gökyer, Ali, Doğan, Mutlu, Bal, Öznur, Çakar, Burcu, Gökmen, Erhan, Yamaç, Deniz, Korkmaz, Taner, Aliyev, Altay, Keskin, Özge, Urvay, Semiha, Büyükşimşek, Mahmut, Karadeniz, Cemile, Yildiz, Birol, Yeşil Çinkir, Havva, Demir, Hacer, Beypinar, İsmail, Karaçin, Cengiz, Eser, Kadir, Baykara, Meltem, Kiliçkap, Saadettin, Okutur, Kerem, Bulut, Gülcan, Alkan, Ali, Arpaci, Erkan, Pilanci, Kezban Nur, Demir, Atakan, Işik, Deniz, Yildirim, Nilgün, ŞİMŞEK, MELİH
Malign mezotelyomada kemoterapi uygulamaları
2022-06-01T00:00:00Z, Şimşek, Melih, Işık, Ulaş, Gürbüz, Orkun, ŞİMŞEK, MELİH
The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib
2021-08-01T00:00:00Z, YILMAZ, Ali, ŞİMŞEK, MELİH, HANNARİCİ, Zekeriya, Buyukbayram, Mehmet E., BİLİCİ, Mehmet, Tekin, Salim B., ŞİMŞEK, MELİH
Aim: To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). Patients & methods: A total of 150 patients with advanced HCC who were treated with sorafenib in our center between January 2011 and December 2019 were included in the study retrospectively. Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and GLR were analyzed to assess their prognostic value using Kaplan-Meier and Cox regression analysis before and after propensity score matching (PSM). Results: In univariate analysis before and after PSM, albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, prognostic nutritional index, AFP level and GLR were found to be significantly associated with both progression-free and overall survival. In multivariate analysis before and after PSM, GLR, albumin-bilirubin grade and AFP were determined to be independent prognostic factors for progression-free and overall survival. Conclusion: The GLR prior to sorafenib treatment is a new prognostic biomarker that may predict survival in advanced HCC.
Immunological Agents Used in Cancer Treatment
2019-02-01T00:00:00Z, Simsek, MELİH, TEKİN, Salim Başol, BİLİCİ, Mehmet, ŞİMŞEK, MELİH
Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), or PD-1 ligand (PD-L1). ICI are approved for the treatment of malign melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and renal cell carcinoma. They can lead to long-term anti-tumor responses by deactivating the brake mechanism in the immune system. Ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab are examples of ICI. CTLA-4 is a brake mechanism in immune response. Ipilimumab and tremelimumab are antibodies against CTLA-4. PD-1 is another important immune checkpoint co-inhibitor receptor that is expressed by activated T cells in the peripheral tissue. As a result of blockage of the PD-1/PD-L1 pathway, local tumor-specific immune response augments, and long-term tumor control can be achieved. In recent years, ICI are approved for the treatment of various malignities. They may be responsible for specific toxicities called immune-related adverse events (irAEs). irAEs are a consequence infiltration of normal tissues by activated T lymphocytes that are responsible for autoimmunity. Corticosteroids and anti-tumor necrosis factor agents, such as infliximab and mycophenolate mofetil, are effective in the treatment of irAEs. Immune checkpoint inhibition with monoclonal antibodies against CTLA-4 and/or PD-1/PD-L1 by single agent or combination treatments became a new option in various solid tumors. However, ICI have unique adverse events, and these adverse events should be considered in any new onset clinical situation and should be managed properly. Future prospective randomized clinical trials will clarify recent questions.
Metachronous bilateral breast cancer diagnosed with primary breast lymphoma and mucinous carcinoma: The first case in the literature
2022-04-01T00:00:00Z, ŞİMŞEK, MELİH, Aykas, Fatma, Yildirim, Ahmet Ozgen, ŞİMŞEK, MELİH
© 2022 Journal of Cancer Research and Therapeutics.Introduction: Breast cancer is the most common cancer in women and 2-11% of the cases are bilateral. Bilateral breast cancer frequently emerges as a second primary cancer. Lymphoma and mucinous carcinoma of breast are very rare. Here we present a case, of bilateral breast cancer with metachronous lymphoma and mucinous carcinoma. Case History: 57-year old female had received chemotherapy and radiotherapy for stage IA Diffuse Large B Cell Lymphoma (DLBCL) located in right breast. At 14th month of her breast DLBCL diagnosis, a diagnosis of mucinous carcinoma was determined in her left breast. After surgery, adjuvant anastrozole was initiated. The patient is still in follow-up with remission at her sixth year of DLBCL diagnosis and fifth year of mucinous carcinoma diagnosis. Conclusions: The evaluation of unilateral breast cancer patients in terms of bilateral breast cancer occurrence risk has become important.
- 1 (current)